Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
Before joining Raw Story, Brad Reed spent eight years writing about technology at BGR.com and Network World. Prior to that, he wrote freelance stories for political publications such as AlterNet ...